S Hoger1, K Lykens2, S F Beavers3, D Katz3, T L Miller2. 1. Tarleton State University, Fort Worth, Texas, USA. 2. University of North Texas Health Science Center, Fort Worth, Texas, USA. 3. Centers for Disease Prevention and Control, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Evidence of substantial, quantifiable and preventable burdens of mortality hazard even after anti-tuberculosis treatment and cure would be a compelling, concrete, and useful measure of the value of prevention. METHODS: We compared years of potential life lost between a cohort of 3 933 cured tuberculosis (TB) patients and 9 166 persons with latent tuberculous infection. We constructed a regression model to predict the expected years of potential life lost in each cohort and for demographic subgroups. RESULTS: Among decedents, a history of fully treated TB is associated with a predicted average 3.6 more years of potential life loss than a comparable population without active TB. Greater longevity losses were predicted among those identified as White and Hispanic than among Black and Asian counterparts. CONCLUSION: We found significant differences in predicted longevity of treated TB survivors relative to a similar group without active TB. These excess losses are substantial: a total of 14 158 life-years or the equivalent of more than 188 75-year lifespans. These findings illustrate an important opportunity cost associated with each preventable TB case - an average of 3.6 potential years of life. We conclude that substantial preventable mortality burdens remain despite adequate anti-tuberculosis treatment, a compelling rationale for more widespread and systematic use of prevention.
BACKGROUND: Evidence of substantial, quantifiable and preventable burdens of mortality hazard even after anti-tuberculosis treatment and cure would be a compelling, concrete, and useful measure of the value of prevention. METHODS: We compared years of potential life lost between a cohort of 3 933 cured tuberculosis (TB) patients and 9 166 persons with latent tuberculous infection. We constructed a regression model to predict the expected years of potential life lost in each cohort and for demographic subgroups. RESULTS: Among decedents, a history of fully treated TB is associated with a predicted average 3.6 more years of potential life loss than a comparable population without active TB. Greater longevity losses were predicted among those identified as White and Hispanic than among Black and Asian counterparts. CONCLUSION: We found significant differences in predicted longevity of treated TB survivors relative to a similar group without active TB. These excess losses are substantial: a total of 14 158 life-years or the equivalent of more than 188 75-year lifespans. These findings illustrate an important opportunity cost associated with each preventable TB case - an average of 3.6 potential years of life. We conclude that substantial preventable mortality burdens remain despite adequate anti-tuberculosis treatment, a compelling rationale for more widespread and systematic use of prevention.
Authors: Anna Peeters; Jan J Barendregt; Frans Willekens; Johan P Mackenbach; Abdullah Al Mamun; Luc Bonneux Journal: Ann Intern Med Date: 2003-01-07 Impact factor: 25.391
Authors: Juan-Pablo Millet; Angels Orcau; Cristina Rius; Marti Casals; Patricia Garcia de Olalla; Antonio Moreno; Jeanne L Nelson; Joan A Caylà Journal: PLoS One Date: 2011-09-28 Impact factor: 3.240
Authors: Suzanne F Beavers; Lisa Pascopella; Amy L Davidow; Joan M Mangan; Yael R Hirsch-Moverman; Jonathan E Golub; Henry M Blumberg; Risa M Webb; Rachel A Royce; Susan E Buskin; Michael K Leonard; Paul C Weinfurter; Robert W Belknap; Stephen E Hughes; Jon V Warkentin; Sharon F Welbel; Thaddeus L Miller; Saini R Kundipati; Michael Lauzardo; Pennan M Barry; Dolly J Katz; Denise O Garrett; Edward A Graviss; Jennifer M Flood Journal: Ann Am Thorac Soc Date: 2018-06
Authors: Serena P Koenig; Ahra Kim; Bryan E Shepherd; Carina Cesar; Valdilea Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramírez; Eduardo Gotuzzo; Catherine C McGowan; Timothy R Sterling; Jean W Pape Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: A R Piñeros; L W Campos; D M Fonseca; T B Bertolini; A F Gembre; R Q Prado; J C Alves-Filho; S G Ramos; M Russo; V L D Bonato Journal: Sci Rep Date: 2017-01-27 Impact factor: 4.379
Authors: Yvetot Joseph; Zhiwen Yao; Akanksha Dua; Patrice Severe; Sean E Collins; Heejung Bang; Marc Antoine Jean-Juste; Oksana Ocheretina; Alexandra Apollon; Margaret L McNairy; Kathryn Dupnik; Etienne Cremieux; Anthony Byrne; Jean W Pape; Serena P Koenig Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396